LEXINGTON, MA--(Marketwired - Feb 6, 2017) - Aldeyra Therapeutics, Inc. (
Event: 2017 Rare Disease, Biopharma One-on-One Day
Date: Tuesday, February 7, 2017
Location: Intercontinental Barclay, 111 E 48th St, New York, NY
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.
Contact Information:
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443